Kuli olonjila vialua vioku sakula uveyi wo kanser yo prostata, pole, onjila yaco yi tiamisiwila kocitumãlo kuenda ndomo uveyi waco u kasi.
Vimue pokati kolonjila vioku sakula mua kongela:
1. Oku lavulula ciwa: Onjila eyi yi lomboloka oku lavulula ciwa uvei wo kanser poku u kũlĩhĩsa olonjanja viosi kuenda oku linga oloseteko vikuavo, okuti ka ci sukila oku fetika lonjanga oku u sakula.
Ci tava okuti ci kuatisa alume vana va kuete uvei wo kanser yo prostata.
Ci tava okuti yi kapiwako koku sakula uveyi wo kanser wo prostata okuti wa lisanduila kolonepa vikuavo vietimba.
6. Oku sakula uvei wo kanser: Uvei waco u kuatisa etimba oku liyaka luvei waco.
Ci tava okuti ci kapiwako koku sakula uveyi wo kanser wo prostata okuti ka u kasi oku tambuluiya ciwa kovihemba vikuavo.
7. Oku sakula kuaco ku kapiwa kovimatamata vimue vi kuatisa ombuto yuveyi wo kanser oku kula kuenda oku amamako lomuenyo.
Ci tava okuti ci kapiwako koku sakula uveyi wo kanser wo prostata okuti ka u kasi oku tambuluiya ciwa kovihemba vikuavo.
8. Oku sakula lombambi yalua: Uloño waco u kuatisa oku tutuiya kuenda oku ponda olosinga vi kuete uvei wo kanser.
Ci tava okuti yi kapiwavo komanu vana va kuete uvei wo kanser yo prostata okuti, ndopo wa fetika ale oku sakuiwa.
9. High-intensity focused ultrasound (HIFU): Oku sakula kuaco ku talavaya lolombindikiyo viondalu oco vi tokote kuenda oku nyõla olosinga viocilenda.
Ci tava okuti yi kapiwavo komanu vana va kuete uvei wo kanser yo prostata okuti, ndopo wa fetika ale oku sakuiwa.
10. Oku lavulula: Onjila eyi yi lomboloka oku lavulula ciwa uvei wo kanser poku u kũlĩhĩsa olonjanja viosi kuenda oku linga oloseteko, pole oku fetika lika ovihemba nda kua molẽha ale oku pongoloka kuolondimbukiso viaco.
Ci tava okuti ci kuatisa alume vana okuti akulu vendamba haivo va kuete uveyi wo kanser yo prostata okuti u livokiya levando kuenda uvei ukuavo.
Ci kuete esilivilo oku vangula eci catiamẽla koku sakuiwa kuosi ku lingiwa la vakuakusakula oco va limbuke onjila ya sunguluka yoku sakuiwa.
Wang Y, Chen J, Wu Z, Ding W, Gao S, Gao Y, Xu C: Mechanisms of enzalutamide resistance in castration-resistant prostate cancer and therapeutic strategies to overcome it. Br J Pharmacol. 2021, 178 (2): 239-261.
Talkar SS, Patravale VB: Gene Therapy for Prostate Cancer: A Review. Endocr Metab Immune Disord Drug Targets. 2021, 21 (3): 385-396.
Šamija I, Fröbe A: CHALLENGES IN MANIPULATING IMMUNE SYSTEM TO TREAT PROSTATE CANCER. Acta Clin Croat. 2019, 58 (Suppl 2): 76-81.
Akaza H, Hinotsu S, Usami M, Ogawa O, Kagawa S, Kitamura T, Tsukamoto T, Naito S, Hirao Y, Murai M, Yamanaka H, Namiki M: The case for androgen deprivation as primary therapy for early stage disease: results from J-CaP and CaPSURE. J Urol. 2006, 176 (6 Pt 2): S47-9.
Abraham-Miranda J, Awasthi S, Yamoah K: Immunologic disparities in prostate cancer between American men of African and European descent. Crit Rev Oncol Hematol. 2021, 164 (): 103426.
de Vrij J, Willemsen RA, Lindholm L, Hoeben RC, Bangma CH, Barber C, Behr JP, Briggs S, Carlisle R, Cheng WS, Dautzenberg IJ, de Ridder C, Dzojic H, Erbacher P, Essand M, Fisher K, Frazier A, Georgopoulos LJ, Jennings I, Kochanek S, Koppers-Lalic D, Kraaij R, Kreppel F, Magnusson M, Maitland N, Neuberg P, Nugent R, Ogris M, Remy JS, Scaife M, Schenk-Braat E, Schooten E, Seymour L, Slade M, Szyjanowicz P, Totterman T, Uil TG, Ulbrich K, van der Weel L, van Weerden W, Wagner E, Zuber G: Adenovirus-derived vectors for prostate cancer gene therapy. Hum Gene Ther. 2010, 21 (7): 795-805.
Lee E, Ha S, Logan SK: Divergent Androgen Receptor and Beta-Catenin Signaling in Prostate Cancer Cells. PLoS One. 2015, 10 (10): e0141589.
['Oku yuvula oku litenga vovitangi:']
['O Web site eyi, ya sandekiwila lika oku longisa omanu kuenda oku va ĩha olonumbi.']
['Nda o yongola oku sakuiwa, sandiliya ondotolo yi kuete uloño woku ci linga.']
['Kũlĩhĩsa okuti, uloño woku konomuisa atambululo apulilo, ka u pondola oku eca atambululo a suapo, ca piãla enene nda etendelo liaco ka lia suilepo.']
['Olonjanja viosi sandiliya ekuatiso liondotolo yove ale liondotolo yikuavo ya loñoloha kueci catiamẽla kocitangi cimue cuhayele. Lalimue eteke ku ka sepule ekuatiso liondotolo ale oku livala koku sandiliya omo liocina cimue wa tanga vo website yilo. Nda o sima okuti o kuete ocitangi cimue cuhayele, vilikiya lonjanga o 911 ale enda lonjanga kosipitali. Ka kuli ukamba umue pokati kondotolo lukuenje wa vela omo lio website yilo ale oku talavaya layo.']
['Oku liyelisa: omoko yoku soneha']
['O Digital Millennium Copyright Act yo 1998, 17 U.S.C. § 512 (o DMCA) yeca epondolo kolonalavayi vi kuete omoko yoku linga eci va sima okuti ovina vi sangiwa vo Internet vi nyõla omoko yavo yi sangiwa vocihandeleko co Estados Unidos. ']
['Nda ove o tava okuti ovina vimue via kapiwa vo Internet ale vovipama vikuavo vi kasi vonumbi yetu vi nyõla omoko yove yoku panga alivulu, ove (ale omunu wa ku nõla) o pondola oku tu tumisa esapulo limue oco tu piñale ovina viaco ale oku vi tateka.']
['Asapulo te a tumiwa loku soneha kuenda vo email (tala vokakasia "Kontato" oco o sange onumbi yo email).']
['DMCA yi kisika okuti esapulo liove lioku lavisa ovihandeleko viovihandeleko viupange mua kongela asapulo akuãimo: (1) elomboluilo liupange u kuete ovihandeleko viupange okuti owo wa lavisiwa; (2) elomboluilo liupange u kuete ovihandeleko viupange kuenda asapulo a tẽla oku ecelela oku sanga upange waco; (3) asapulo oku ku sandiliya, oku kongelamo onumbi yove, etendelo liotelefone kuenda onumbi yo email; (4) esapulo liove okuti ove o kuete ekolelo liwa okuti upange waco ka wa taviwile la muẽliaco ovihandeleko viupange, ale onumiwa yaye, ale oku kuama ovihandeleko; ']
['(5) ukanda umue wa sinaliwa love okuti u lekisa okuti esapulo liaco liocili kuenda o kuete omoko yoku teyuila omoko yove yoku soneha.']
['Kuenda (6) ondimbukiso yocikuata ale yo komputador yomunu ukuete omoko yoku linga upange waco ale yomunu umue o kuete omoko yoku linga upange waco vonduko yomunu ukuete omoko yaco. ']
['Nda kua kongelele ulandu wosi wa tukuiwa ndeti, ci tava okuti o livala poku tetulula ocitangi cove.']
['Oku Sapela']
['Tu tumise o email lapulilo ale ovisimĩlo viove.']
How to treat prostate cancer?
There are several treatment options available for prostate cancer, depending on the stage and aggressiveness of the cancer, as well as the patient's overall health and personal preferences.
Some common treatments include:
1. Active surveillance: This approach involves closely monitoring the cancer with regular checkups and tests, rather than immediately starting treatment.
It may be suitable for men with low-risk prostate cancer.
2. Surgery: A prostatectomy is a surgical procedure to remove the prostate gland.
It can be done through open surgery or laparoscopically (using small incisions and specialized tools).
3. Radiation therapy: This treatment uses high-energy radiation to kill cancer cells.
It can be delivered externally (from a machine outside the body) or internally (through implants placed near the tumor).
4. Hormone therapy: This treatment reduces the levels of male hormones (androgens) in the body, which can slow or stop the growth of prostate cancer.
It can be used alone or in combination with other treatments.
5. Chemotherapy: This treatment uses drugs to kill cancer cells.
It may be used for advanced prostate cancer that has spread to other parts of the body.
6. Immunotherapy: This treatment helps the immune system fight cancer.
It may be used for advanced prostate cancer that has not responded to other treatments.
7. Targeted therapy: This treatment targets specific genes or proteins that help cancer cells grow and survive.
It may be used for advanced prostate cancer that has not responded to other treatments.
8. Cryotherapy: This treatment uses extreme cold to freeze and kill cancer cells.
It may be used for early-stage prostate cancer or for cancer that has come back after other treatments.
9. High-intensity focused ultrasound (HIFU): This treatment uses high-frequency sound waves to heat and destroy cancer cells.
It may be used for early-stage prostate cancer or for cancer that has come back after other treatments.
10. Watchful waiting: This approach involves closely monitoring the cancer with regular checkups and tests, but not starting treatment unless symptoms appear or change.
It may be suitable for older men with slow-growing prostate cancer and other serious health conditions.
It is important to discuss all treatment options with a healthcare team to determine the best course of action for each individual case.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['Okuti']
['BioMedLib yi talavaya lolomakina violo computador (oku lilongisa omakina) oco yi linge apulilo kuenda atambululo.']
['Tu fetika leci ci soka 35 kolohuluwa vialivulu a lombolola ovina viatiamẽla kuhayele.']
